Homepage > Company > Media > Pharma News > 2019 > FDA approves Aquestive's ALS treatment

FDA approves Aquestive's ALS treatment

(Reuters) - The U.S. Food and Drug Administration on Friday approved Aquestive Therapeutics' treatment for neurological disorder amyotrophic lateral sclerosis (ALS).

Shares of the company, which developed riluzole oral film (ROF) and will market the film under the brand name Exservan, rose 4% at $6.76 after the bell.

ALS is an ultra-rare neurodegenerative disorder that causes the death of neurons controlling voluntary muscles, with more than 6,000 people diagnosed with the disease in the United States every year, according to the ALS Association.

The New Jersey-based drugmaker earlier this month gave Italian drugmaker Zambon S.p.A. license to develop and sell the drug in the European Union.

NOVEMBER 22, 2019

https://www.reuters.com/

Read also

AskBio’s AB-1002 gene therapy receives FDA Fast-Track status

The US Food and Drug Administration (FDA) has granted fast-track designation to Bayer subsidiary Asklepios BioPharmaceutical’s (AskBio) investigational gene therapy AB-1002, aimed at...

“Lack of harmonisation in Europe” hindering gene therapy growth

The future of cell and gene therapy access in Europe could be more precarious than across the pond.

Moderna stock on track for the eighth consecutive day of losses

Moderna shares are trading in the red on Friday, on track for the eighth consecutive day of losses. Stock down 1.28% at $100.70. MRNA has lost about 29.6% in the last 12 months and YTD, the st...

Alvotech moves to bring its Humira biosimilar to US market

Hot on the heels of a US Food and Drug Administration (FDA) approval for Alvotech and Teva Pharmaceuticals’ Simlandi (adalimumab-ryvk), Alvotech has announced a long-term agreement w...